News | Biogen

September 17, 2021

CHMP Recommends VUMERITY® (diroximel fumarate) for Approval in the European Union as a Treatment for Relapsing-Remitting Multiple Sclerosis

VUMERITY is a next-generation oral fumarate with a well-characterized efficacy and safety profile Data from the Phase 3 EVOLVE-MS-2 study have demonstrated that treatment with VUMERITY results in low discontinuation rates due to its gastrointestinal (GI) tolerability profile Upon approval, VUMERITY

September 16, 2021

Biogen Announces Positive Topline Results from Phase 2 CONVEY Study in Small Fiber Neuropathy

September 15, 2021

Biogen Announces Agenda for Virtual Investor Day R&D Day on September 21, 2021

List View Grid View

December 3, 2019

Biogen Announces Positive Phase 2 Study Results for Cutaneous Lupus Erythematosus (CLE) and Systemic Lupus Erythematosus (SLE)

The Phase 2 LILAC study met its primary endpoints, demonstrating statistically significant reduction of disease activity in patients with CLE and SLE who received BIIB059 compared to placebo Positive results support Biogen’s goal of building a multi-franchise portfolio and underscore the company’s

November 22, 2019

Biogen Presents Data Demonstrating Improved Gastrointestinal Tolerability With VUMERITY™ (diroximel fumarate) Compared to TECFIDERA® (dimethyl fumarate)

CAMBRIDGE, Mass., Nov. 22, 2019 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced detailed results from the Phase 3 EVOLVE-MS-2 study demonstrating the improved patient-assessed gastrointestinal (GI) tolerability of VUMERITY™ (diroximel fumarate), a new FDA-approved treatment for

November 21, 2019

Biogen to Present at the Evercore ISI 2nd Annual HealthCONx Conference

Cambridge, MA, - - Biogen Inc. (Nasdaq: BIIB) announced today that it will present at the Evercore ISI 2nd Annual HealthCONx Conference. The webcast will be live on Tuesday, December 3, at 11:45a.m. ET, with Anirvan Ghosh, Ph.D., Senior Vice President and Head of Research and Early Development at

November 21, 2019

Biogen Announces Enrollment Completion of Global Phase 3 Gene Therapy Study for an Inherited Retinal Disorder

Timrepigene emparvovec is a potential first-in-class AAV2 gene therapy for the treatment of choroideremia, a rare, degenerative, X-linked retinal disorder that leads to blindness CAMBRIDGE, Mass., Nov. 21, 2019 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced today the enrollment of the

November 6, 2019

Biogen to Expand Biosimilars Portfolio and Gain Access to Additional Markets Through New Transaction with Samsung Bioepis

Biogen to gain exclusive commercialization rights to two new ophthalmology biosimilars referencing Lucentis and Eylea in the U.S., Canada, Europe, Japan and Australia Will provide Biogen with commercialization rights for its current anti-TNF biosimilars portfolio in China, adding to its strategic

November 4, 2019

Biogen to Host Investor Webcasts from Clinical Trials on Alzheimer’s Disease (CTAD) Congress on December 5, 2019

CAMBRIDGE, Mass., Nov. 04, 2019 (GLOBE NEWSWIRE) -- Biogen (Nasdaq: BIIB) today announced it will host live webcasts of its oral presentation and a Q&A session related to its Alzheimer’s disease investigational therapy, aducanumab, at the upcoming Clinical Trials on Alzheimer’s Disease (CTAD)

October 30, 2019

Biogen and Alkermes Announce FDA Approval of VUMERITY™ (diroximel fumarate) for Multiple Sclerosis

– VUMERITY, a New Oral Treatment Option for Relapsing Forms of MS, Offers a Combination of Well-Characterized Efficacy, Safety and Tolerability – CAMBRIDGE, Mass. and DUBLIN, Ireland, Oct. 30, 2019 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Alkermes plc (Nasdaq: ALKS) today announced that

October 22, 2019

Biogen Plans Regulatory Filing for Aducanumab in Alzheimer’s Disease Based on New Analysis of Larger Dataset from Phase 3 Studies

New analysis of larger dataset showed that aducanumab reduced clinical decline in patients with early Alzheimer’s disease as measured by the pre-specified primary and secondary endpoints Based on discussions with the FDA, the Company plans to submit a Biologics License Application in early 2020

October 21, 2019

Biogen and Samsung Bioepis to Present Data for Infliximab and Adalimumab Biosimilars at United European Gastroenterology Week

Data highlight s real-world evidence confirming the safety and efficacy of anti-TNF biosimilars for patients with i nflammatory b owel d isease (IBD) CAMBRIDGE, Mass. and INCHEON, Korea, Oct. 21, 2019 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Samsung Bioepis today announced that they will

October 2, 2019

Landmark NURTURE Study of Infants with Spinal Muscular Atrophy (SMA) Treated Pre-Symptomatically with SPINRAZA® (nusinersen) Published in Neuromuscular Disorders

Treatment with SPINRAZA resulted in survival of 100 percent of infants, with none requiring permanent ventilation Motor milestones achieved included 100 percent of participants sitting without support and 88 percent walking independently; unprecedented outcomes in comparison to the natural history